

97 Mt. Bethel Road Warren,NJ 07058 P: 732-595-5414 | F: 732-960-9222 info@clarity-laboratory.com | www.clarity-laboratory.com CLIA # 31D2140149

MOLECULAR DIAGNOSTICS

1 ACCOUNT INFORMATION		2 DATIENT INCORMATION	ON	
ACCOUNT INFORMATION		PATIENT INFORMATION Last Name	ON First No	ame
		LUSI NUITIE	FIISI NO	инь
		D.O.B (MM/DD/YY)		Sex
				□ M □ F
		Phone (Day)	(Evenir	na)
		Thomas (Buy)	(2701111	197
The ordering physician must sign his/her name and indicate		Address		
signature constitutes as a certification, that with repsect to tests or other third party payers that the testing is medically necessar		7.00.000		
management of the patient.	,			
X		City	State	Zip
Physician Signature	Date			
THIS SECTION IS BE TO COMPLETED BY A CLINICIAN VALIDATED RISK ASSESSMENT				
Respiratory Failure Cough	☐ Chills	☐ Hypoxia ☐ Joint Pain	☐ Muscle Pain	☐ No sense of taste or smell
Fever Nasal Discharge (Rhin		Sore Throat Fatigue	Shortness of Breath	☐ Body Ache
3 INSURANCE INFORMATION Client Bil	_			SPECIMEN INFORMATION
Insured's Name (if different from Patient) Policy ID # Specimen Source: □Nasopharyngeal Swab □Throat Swab(only for 4020(SARS-COV-2))				
Primary Insurance Name & Plan / Workers Comp. Carrier	Group/Pla			Date Collected:/
Bullo collisoida.				Time: : DAM DPM
Address (Insurance)		☐ Check Received by:		Collector: AM L PM
A PURSUS CORRE				CONTROL .
4 DIAGNOSIS CODES	□ 111.1 J=#	nidentified influence winner	□ 115.7 Pro	ania due to Museulas
R07.0 Pain in throat J02.9 Acute pharyngitis, unspecified				onia due to Mycoplasma pneumoniae luenza virus pneumonia
☐ J20.8 Acute bronchitis due to other specified	☐ J21.1 Acute bronchiolitis	,		story syncytail virus as the cause of
organisms metapneumovirus diseases classified elsewhere				
☐ J18.9 Pneumonia, unspecified organism ☐ B97.0 Adenovirus as the cause of diseases classified ☐ B34.8 Other viral infections of unspecified site				
□ J16.0 Chlamydial pneumoniaAdenovirus elsewhere □ R06.02 Shortness of breath				
B34.0 infection, unspecified				
diseases classified elsewhere	-		☐ R53.83 Other fo	atique
diseases classified elsewhere				with and (suspected) exposure to other
ICD 10 CODES Please enter diagnosis code(s) in the box	1		mmunicable diseases	
Z03.818 Encounter for observation for suspected exposure to other biological agents ruled out				
PLEASE NOTE: This resource is provided for informational purposes only and does not guarantee that billing codes will be appropriate or that coverage and reimbursement will result. Providers should consult with their payers for all				
relevant coverage coding and reimbursement requirements. It is the sole responsibility of the provider to select proper codes. This resource is not intended as legal advice or a substitute for a provider's independent professional judgement. Clarity Laboratories, LLC, assumes no liability for the results or consequences associated with the use of this quick reference quide and makes no representation, warranty, or guarantee as to the accuracy or validity of any of				
the information contained herein. For comprehensive coding guidance see complete ICD-10-CM code set and Official Coding Guidelines, 2017 edition.				
5 TEST SELECTION				
☐ 4020 (SARS-CoV-2)(Novel Coronavirus for COVII	D-19 only) RPPV (RES	SPIRATORY VIRUS PANEL)**		RESPIRATORY BACTERIA TESTS
_ `		PITORY PATHOGEN PANEL)	4	RPPM Mycoplasma Pneumoniae
_ , ,		1*with SARS-COVID-2)		RPPW Mycopiasina Pileumoniae
□ 4051 (S		S-COVID-2 IgG AntiBody) [SS	T] 🗆	RPPB Bordetella Pertussis
□ 4050 (SARS-COVID-2 w/ reflex to RPP1*)			П	RPPC Chlamydophila Pneumoniae
* Includes all viruses and bacterias listed below. ** Includes only viruses listed below				
VIRUSES: Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, Human Metapneumovirus A/B, Influenza A subtype H1, Influenza A subtype H1N1/2009/pdm09,				
Influenza A subtype H3, Influenza B, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Respiratory Syncytial Virus A/B, Rhinovirus/Enterovirus.				
BACTERIAS: Bordefella perfussis, Chlamydophila pneumoniae, Mycoplasma pneumoniae				
PATIENT CONSENT				
PATIENT CONSENT REIMBURSEMENT: Clarity Labs (CL) will make every reasonable effort to obtain reimbursement for the ordered tests above. I hereby authorize CL to release to Medicare and/or any insurance carrier providingmedical benefits to me and any health plan to which I am a member any and all medical or other information necessary for claims purposes. I hereby authorize payment of medical insurance benefits to the party				
who bills for these claims and accepts assignments. I understand that if my insurance company pays me directly for the services provided by CL that I am responsible for forwarding such payment to CL. I understand that I am				
responsiblefor any outstanding balances, deductible/co-payments as				
the bottom of thisfrom. If Medicare denies payment, I agree to pay for the identified test(s). I understand that CL may use my specimen and any testing performed on that specimen, for research, development, and potential publication purposes, so long as the information has been properly de-identified pursuant to law.				
v				
X DATIENT NAME (plants print)	DATIFAIT	SIGNATURE		DATE
PATIENT NAME (please print) PATIENT SIGNATURE DATE				
IMPORTANT MEDICARE INFORMATION TO THE BENEFICIARY: ADVANCED BENIFICIARY NOTICE (ABN) Your physician may sometimes order laboratory testing that he or she believes to be necessary for your care, but which does not quality for coverage under your Insurance Provider's and Medicare's standards. Insurance Providers				
and Medicare will only pay for services that it determines to be "reasonable and necessary" based upon the diagnosis information furnished to Clarity Laboratory by your physician. If, under your Insurance Provider's and				
Medicare's standards, your diagnosis does not support the testing ordered, your Insurance Providers and Medicare will deny coverage. In those cases where your Insurance Providers and Medicare denies coverage, the billing will be forwarded to you, and you will be responsible for the cost of the laboratory tests.				
FOR LAB USE ONLY		FOR LAB USE ONLY		
T:				
Received by: lime:	: AM PM			

SPECIMEN REQUIREMENTS

SPECIMEN SOURCE

Nasal, Throat

COLLECTION MEDIA

Nasopharyngeal Swab (UTM Swab) Oropharyngeal Swab (Eswab) Serum Seperation Tube (SST)

SPECIMEN PREPARATION

Place the swab in Universal Transport Media (UTM) or ESwabs. Place each specimen in an individually sealed baa

UNACCEPTABLE CONDITIONS

Specimens not in Universal Transport Media (UTM) or ESwabs

Broken Sample Collection Tubes

TURN AROUND TIME

24 hours

TEST PERFORMED

7 days

Nasopharyngeal specimen's storage condition is listed below:

- Room temperature up to 4 hours (15-25 C)
- Refrigerated up to 3 days at 2-8 C
- Frozen sample up to 30 days at -15 to -25 C
 Clarity labs recommends all samples collected must be stored in a refrigerator prior to courier handling.
 When storing samples in the specimen box or shipping out by Fed-Ex or UPS, the UTM SWAB must be stored with cold pack.

SPECIMEN REQUIREMENTS for 4051(SARS-CoV-2 IgG Antibody)

SPECIMEN SOURCE

Blood

COLLECTION MEDIA

Serum Seperation Tube (SST)

UNACCEPTABLE CONDITIONS

Broken Sample Collection Tubes

TURN AROUND TIME

24 - 48 hours

TEST PERFORMED

7 days

SST specimen's storage condition:


• Frozen sample up to 30 days at -15 to -25 C

• Room temperature up to 4 hours (15-25 C)


 Refrigerated up to 3 days at 2-8 C
 Clarity labs recommends all samples collected must be stored in a refrigerator prior to courier handling.
 When storing samples in the specimen box or shipping out by Fed-Ex or UPS, the SST must be stored with cold pack.

Nasopharyngeal and Oropharyngeal Swab Specimen Collection Procedure

Proper collection and handling of patient specimens are of utmost importance in respiratory virus detection



Open the sterile, flexible minitipped swab package and remove the swab.




Tilt the patient's head back (head should be inclined from vertical)



Gently insert the sterile swab along the nasal septum just above the floor of the passage to the nasopharynx until resistance is met.



This step is recommended onlyfor4020(SARS-COV-2) in addition to step 3a. Sticking out the patient's tongue, use a sterile swab to swab the posterior nasopharynx and tonsillar arches. (Proceed to step-5)




Rotate the swab gently against the nasopharyngeal mucosa for 10-15 seconds and gently remove the swab.



Insert the swab into the UTM tube pushing it all the way to the bottom of the tube.



Holding the swab shaft close to the rim of the tube and point the tube away, break the swab shaft along the prescored breakpoint indentation.



Label specimen appropriatly including two patient identifiers, (e.g. patient name, and date of birth), specimen source and date and time of collection.



If you are shipping the specimen via the enclosed pre-paid FedEx Clinical Pak, UPS, please make sure that the specimen container is first placed into a specimen bag, that you have enclosed pre-paid label to the front of the clinical Pak.

Transport the specimen to the lab after collection. If specimen delivery will be delayed the specimen may be stored at 2 - 8°C using cold packs, wet or other refrigerant coolants for up to 7 days. If longer storage is required, the specimen should be frozen at -70°C.



UPS , FedEx or Call Clarity Labs for pick-up service.

NOTE: When using the Clarity Labs courier, please ensure that specimen is in the specimen box with a refrigerated cold pack. Courier pickup is available seven days a week.